DeepMed Research

Chinese Academy of Medical Sciences

🇨🇳China

Country: 🇨🇳China

Ownership: Private, Subsidiary

Established: 2004-07-08

Employees: -

Market Cap: -

Website: http://www.pinganzhengxing.com

Clinical Trials

The Effect of Bone Marrow-sparing Intensity-Modulated Radiotherapy to GI Cancer

Conditions: Gastric Cancer
Adverse Effect of Radiation Therapy
Rectal Cancer
Bone Marrow Toxicity

Interventions: Radiation: Bone Marrow-sparing Intensity-Modulated Radiotherapy

First Posted Date: 2013-05-29

Last Posted Date: 2013-05-29

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 58

Registration Number: NCT01863420

Locations: 🇨🇳
Department of Radiation Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, Beijing, China

Sequential Use of Low-dose Sunitinib With Chemotherapy in Advanced NSCLC After Failure of Conventional Regimen

Phase 2

Conditions: Cancer
Lung Cancer

Interventions: Drug: Sunitinib, chemotherapy

First Posted Date: 2013-05-09

Last Posted Date: 2013-05-09

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 50

Registration Number: NCT01850147

Locations: 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, China

The Role of Concurrent Chemotherapy for Lower Risk Locally Advanced Nasopharyngeal Carcinoma(NPC) in the Era of IMRT

Phase 3

Conditions: Nasopharyngeal Carcinoma

Interventions: Radiation: SIB-IMRT
Drug: Cisplatin

First Posted Date: 2013-03-22

Last Posted Date: 2021-01-29

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 590

Registration Number: NCT01817023

Locations: 🇨🇳
Jiangxi province cancer hospital, Nanchang, Jiangxi, China
🇨🇳
Department of Radiation oncology, Cancer hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China
🇨🇳
Cancer hospital, Chinese Academy of Medical Sciences, Beijing, China

and more 3 locations

The Role of Induction Chemotherapy for High-risk Locally Advanced Nasopharyngeal Carcinoma in the Era of IMRT

Phase 2

Completed

Conditions: Nasopharyngeal Neoplasms

Interventions: Drug: Cisplatin
Drug: Paclitaxel
Radiation: IMRT

First Posted Date: 2013-02-25

Last Posted Date: 2014-09-10

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 130

Registration Number: NCT01797900

Locations: 🇨🇳
Department of Radiation Oncology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China

Cisplatin,Docetaxel and S-1 for Advanced Gastric and Gastroesophageal Junction Cancer

Phase 2

Conditions: Gastric Cancer
Gastroesophageal Junction Cancer

Interventions: Drug: Docetaxel
Drug: Cisplatin
Drug: S-1

First Posted Date: 2012-12-12

Last Posted Date: 2012-12-12

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 40

Registration Number: NCT01747707

Locations: 🇨🇳
Cancer Hospital & Institute, Chinese Academy of Medical Sciences, Beijing, China

Efficacy of Intensity Modulated Radiation Therapy After Surgery in Early Stage of Esophageal Carcinoma;

Phase 3

Conditions: Esophageal Neoplasm
Esophageal Cancer TNM Staging Primary Tumor (T) T2
Esophageal Cancer TNM Staging Primary Tumor (T) T3
Esophageal Cancer TNM Staging Regional Lymph Nodes (N) N0
Esophageal Cancer TNM Staging Distal Metastasis (M) M0

Interventions: Radiation: Prophylactic postoperative radiation therapy

First Posted Date: 2012-12-07

Last Posted Date: 2019-01-31

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 240

Registration Number: NCT01745107

Locations: 🇨🇳
Cancer institute & Hospital，Chinese Academy of Medical Science, Beijing, Beijing, China

Study of Bevacizumab Plus Chemotherapy in Patients With Metastatic Colorectal Cancer

Phase 2

Conditions: Colorectal Cancer

Interventions: Drug: Oxaliplatin
Drug: Xeloda
Drug: Calcium folinate (CF)
Drug: 5-FU
Drug: Bevacizumab

First Posted Date: 2012-09-06

Last Posted Date: 2012-09-06

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 100

Registration Number: NCT01679327

Locations: 🇨🇳
Cancer Institute&Hospital Chinese Academy of Medical Sciences, Beijing, China

Postoperative IMRT Combined With Capecitabine for Advanced Gastric Cancer Patients

Phase 2

Conditions: Gastric Cancer

Interventions: Radiation: concurrent chemoradiation

First Posted Date: 2012-08-29

Last Posted Date: 2015-02-05

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 40

Registration Number: NCT01674959

Locations: 🇨🇳
Dept of Radiation oncology, Cancer Hospital , Chinese Academy of Medical Science, Beijing, Beijing, China

Clinical Study of Albumin-bound Paclitaxel Plus Nedaplatin in Cervical Cancer

Phase 2

Conditions: Uterine Cervical Cancer

Interventions: Drug: albumin-bound paclitaxel plus nedaplatin

First Posted Date: 2012-08-17

Last Posted Date: 2012-08-22

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 30

Registration Number: NCT01667211

Locations: 🇨🇳
Chinese Academy of Medical Sciences, Cancer Hospital, Gynecologic Oncology, Beijing, China

A Phase II Study of Amifostine for the Prevention of Acute Radiation-Induced Rectal Toxicity

Phase 2

Conditions: Rectal Cancer

Interventions: Drug: Amifostine

First Posted Date: 2012-04-26

Last Posted Date: 2013-08-15

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 40

Registration Number: NCT01586117

Locations: 🇨🇳
Radiation Oncology Depratment, Cancer Hospital, CAMS, Beijing, Beijing, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy